Keyphrases
Lead Optimization
100%
PIM-1
96%
Purine
80%
MPS1
80%
TTK Inhibitor
80%
Orally Bioavailable
80%
Synthetic Evaluation
80%
Pyrazolo
80%
Biological Evaluation
80%
Potential Treatments
80%
Urothelial Carcinoma
80%
Cancer Resistance
80%
Small Molecule Inhibitors
80%
Elephant
80%
Pyrimidine
80%
PIM Kinase
80%
Oral Bioavailability
69%
Invasive Urothelial Carcinoma
32%
Family Members
32%
Human Control
30%
HCT-116 Cell Line
26%
ADME Properties
26%
On-target Activity
26%
Biochemical Activity
26%
Cytotoxicity
26%
Physicochemical Properties
26%
Biological Activity
26%
Mechanism-based
26%
Li-Fraumeni Syndrome
24%
Virtual Screening
20%
FMS-like Tyrosine Kinase 3 (FLT3)
20%
Chemical Synthesis
20%
HERG
20%
Colony Formation
20%
Safety Profile
20%
Oncogenic Kinases
20%
Cell Behavior
20%
Cell-based
20%
Highly Selective
20%
Therapeutic Agents
20%
Survival Study
20%
Increased Safety
20%
Potent Inhibitor
20%
Selective Inhibitor
20%
Phosphorylation
20%
African Elephant
18%
High-grade Urothelial Carcinoma
16%
Integration Site
16%
Targets for Therapy
16%
Downstream Effectors
16%
Medicine and Dentistry
Kinase
80%
Cancer Resistance
80%
Li-Fraumeni Syndrome
80%
DNA Damage Response
80%
Transitional Cell Carcinoma
80%
Bladder Cancer Cell Line
32%
Tumor-Related Gene
20%
Human Physiology
20%
Evolutionary Medicine
20%
DNA Repair
20%
Pharmacodynamics
16%
Cytochrome P450
16%
Aciclovir
16%
Neoplasm
16%
Leukemia
16%
Colony Formation
16%
Biological Marker
16%
Diethyl Ether
16%
Xenograft
16%
Phosphotransferase
16%
Proteus Syndrome
16%
Surgery
16%
Bioavailability
16%
Cell Cycle
16%
Cancer Cell
16%
Phosphotransferase Inhibitor
16%
Cell Proliferation
16%
Programmed Cell Death
16%
Cell Signaling Pathway
16%
Head and Neck Cancer
16%
Multiple Myeloma
16%
S Phase
16%
Proto Oncogene
16%
Disease Exacerbation
16%
Biopsy Technique
16%
Protein Serine Threonine Kinase
16%
Tumor Progression
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cancer Resistance
80%
Pyrimidine
80%
Transitional Cell Carcinoma
80%
Li-Fraumeni Syndrome
64%
Absorption Distribution Metabolism Excretion
40%
Target Activity
40%
Bladder Cancer
32%
Virtual Screening
26%
Protein BAD
26%
Lead Compound
26%
Protein Serine Threonine Kinase
16%
Disease Exacerbation
16%
Pharmacodynamics
16%
Leukemia
16%
Cytochrome P450
16%
Bioavailability
16%
Lion
16%
Biological Marker
16%
Head and Neck Cancer
16%
Hyrax
16%
Multiple Cancer
16%
Malignant Neoplasm
16%
Tumor Growth
16%
Multiple Myeloma
16%
Phosphotransferase
16%
Phosphotransferase Inhibitor
16%
Neoplasm
16%
Aciclovir
16%
Molecular Target
16%
